Xenon Pharmaceuticals Inc.
XENE
$34.70
-$0.41-1.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -46.81% | -29.57% | -22.05% | -14.87% | -19.65% |
| Total Depreciation and Amortization | 200.64% | -61.42% | 9.47% | 69.21% | -222.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -17.08% | 510.43% | 114.90% | 122.94% | 231.80% |
| Change in Net Operating Assets | 958.04% | 72.38% | 46.39% | -320.56% | -123.92% |
| Cash from Operations | -53.63% | -6.38% | 1.63% | -25.48% | -8.15% |
| Capital Expenditure | -903.85% | 50.83% | 29.02% | 91.48% | 95.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 141.42% | -95.33% | 273.67% | -194.24% | -1,805.05% |
| Cash from Investing | 141.08% | -96.33% | 296.81% | -199.10% | -1,572.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.26% | -- | -- | -- | 5,400,133.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -96.26% | -- | -- | -- | 5,400,133.33% |
| Foreign Exchange rate Adjustments | -570.33% | 118.75% | -156.27% | -722.03% | -69.78% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 12.27% | -240.23% | 1,669.31% | -831.43% | 206.10% |